CohBar Inc (CWBR)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Joseph J. Sarret |
| Employees: | 10 |
| Web site: | cohbar.com |
|
1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK, CA, 94025
(650) 446-7888
| |
| Date | Ratio |
|---|---|
| 2022-09-23 | 1:30 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for NASH and obesity.
Please log in first to see chart